We are live on ! Find out more
DFTX

Definium Therapeutics

176 hedge funds and large institutions have $72.4M invested in Definium Therapeutics in 2021 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 54 increasing their positions, 35 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more call options, than puts

Call options by funds: $5.21M | Put options by funds: $2.36M

54% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 35

28% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 29

1% more funds holding

Funds holding: 174176 (+2)

0.05% less ownership

Funds ownership: 0.87%0.82% (-0.05%)

31% less capital invested

Capital invested by funds: $105M → $72.4M (-$32.4M)

Holders
176
Holders Change
+2
Holders Change %
+1.15%
% of All Funds
2.71%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
37
Increased
54
Reduced
35
Closed
29
Calls
$5.21M
Puts
$2.36M
Net Calls
+$2.85M
Net Calls Change
+$1.65M

DFTX Hedge Fund Activity: Q4 2021 in Review

176 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q4 2021, worth a combined $72.4M — down 31% from $105M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new DFTX positions and 29 closed out — a net gain of 8 holders — while 54 added to existing stakes and 35 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $4.69M. The largest seller was Goldman Sachs, cutting an estimated $1.68M.

  • 176 institutional investors held Definium Therapeutics (DFTX) as of Q4 2021, up from 174 in Q3 2021.
  • Funds reported $72.4M of Definium Therapeutics stock for Q4 2021, down 31% quarter-over-quarter.
  • 37 funds opened new Definium Therapeutics positions in Q4 2021 and 29 closed out, a net change of +8 holders.
  • The largest Definium Therapeutics buyer in Q4 2021 was Morgan Stanley, an estimated $4.69M added.
  • The largest Definium Therapeutics seller in Q4 2021 was Goldman Sachs, an estimated $1.68M sold.

Based on aggregated 13F filings for Q4 2021.